Myeloid Neoplasms with Germline Predisposition.

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• The 2016 World Health Organization (WHO) classification introduced "myeloid neoplasms with germline predisposition."
• These rare conditions are frequently underdiagnosed and underreported, impacting patient care and family screening.
• Understanding these predispositions is crucial for timely diagnosis and management.

Purpose of the Study:

• To highlight the significance of recognizing myeloid neoplasms with germline predisposition.
• To outline the diagnostic criteria and challenges associated with these rare entities.
• To emphasize the implications for patient and family genetic counseling and clinical management.

Main Methods:

• Review of the 2016 WHO classification criteria for myeloid neoplasms with germline predisposition.
• Discussion of diagnostic approaches including clinical history, bone marrow morphology, and molecular testing.
• Emphasis on germline DNA evaluation to confirm mutations and differentiate from somatic variants.

Main Results:

• Myeloid neoplasms with germline predisposition are categorized into three groups based on clinical history.
• Specialized molecular testing, including germline DNA evaluation, is essential for accurate diagnosis.
• Bone marrow examinations are recommended for baseline assessment and monitoring disease progression.

Conclusions:

• Accurate diagnosis of myeloid neoplasms with germline predisposition requires a multidisciplinary approach.
• Early recognition and diagnosis are critical for appropriate therapy and family risk assessment.
• Advanced molecular techniques are often necessary to identify unique familial mutations.